Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy

Hodgkin Lymphoma, Adult Clinical Trial

— HODGSA  

Official title:

Outcome of Hodgkin Lymphoma Patients Over Than 60 Years Treated by Chemotherapy and/or Radiotherapy: a Retrospective Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03535948
• Other study ID #: PSS2016/hodgSA-CLEMENT-F/AS
• Status: Active, not recruiting
• Start date: May 15, 2018
• Est. completion date: December 2019

Study information

• Verified date: May 2019
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Outcome of Hodgkin lymphoma patients over than 60 years treated by chemotherapy and/or radiotherapy: retrospective analysis.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 90
• Est. completion date: December 2019
• Est. primary completion date: November 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Patients over than 60 years

• Newly diagnosed Hodgkin lymphoma

Exclusion Criteria:

• Data not available

Related Conditions & MeSH terms

• Hodgkin Disease
• Hodgkin Lymphoma, Adult
• Lymphoma

Locations

Country	Name	City	State
France	CHU Dijon	Dijon
France	CHRU Nancy	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months	Time between diagnosis and progression or death - up to 100 weeks